US3682835A - Liquid blood serum control standard - Google Patents

Liquid blood serum control standard Download PDF

Info

Publication number
US3682835A
US3682835A US92533A US3682835DA US3682835A US 3682835 A US3682835 A US 3682835A US 92533 A US92533 A US 92533A US 3682835D A US3682835D A US 3682835DA US 3682835 A US3682835 A US 3682835A
Authority
US
United States
Prior art keywords
serum
blood serum
control standard
sodium
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US92533A
Inventor
Allan L Louderback
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Baxter Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Laboratories Inc filed Critical Baxter Laboratories Inc
Application granted granted Critical
Publication of US3682835A publication Critical patent/US3682835A/en
Assigned to COOPER LABORATORES, INC. reassignment COOPER LABORATORES, INC. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BAXTER TRAVENOL LABORATORIES, INC., A CORP. OF DE
Assigned to TECHNICON INSTRUMENTS CORPORATION, 511 BENEDICT AVENUE, TARRYTOWN, NEW YORK 10591-6097, A CORP. OF DE. reassignment TECHNICON INSTRUMENTS CORPORATION, 511 BENEDICT AVENUE, TARRYTOWN, NEW YORK 10591-6097, A CORP. OF DE. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: COOPER LABORATORIES, INC.,
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/04—Processes using organic exchangers
    • B01J39/05—Processes using organic exchangers in the strongly acidic form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/80—Multi-analyte reference solutions containing cholesterol, glucose and the like
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/102499—Blood gas standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/103332—Bilirubin or uric acid standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/104165—Lipid, cholesterol, or triglyceride standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/104998—Glucose, ketone, nitrate standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/109163—Inorganic standards or controls

Definitions

  • a liquid control standard for use in the analysis of blood serum which standard is prepared from anticoagulantstored blood plasma by treating the defibrinated plasma with ion exchange resin to reduce the alkali and alkalineearth metal cation level followed by drying, removing the lipoprotein component by extraction with a fat solvent and then reconstituting the product with water.
  • This invention relates to a liquid blood serum control standard and method of preparation thereof.
  • Blood serum is a complex biological fluid containing numerous components of substantial physiological importance. In the normal or average healthy person the concentrations of these components fall within certain reasonably well-defined limits. When one or more of these components is determined upon analysis to fall outside of these acceptable limits, various diseases or pathological conditions of the body systems are indicated.
  • control standards used in actual practice is the freeze-dried serum which is reconstituted with aqueous ammonium bicarbonate prior to use as described in US. Pat. 3,466,249.
  • a complete liquid control standard which does not require such reconstitution would be convenient and find much use in practice.
  • liquid blood serum is treated with a strong acid cation exchange resin to reduce the sodium, potassium and calcium level in the serum, and the pH of the serum is maintained at, or adjusted to, about its original level by sufficient alkaline reagent which does not contain any sodium, potassium, calcium or ammonium ions.
  • the resin-treated and pH-adjusted serum is then dried and the lipoprotein component is extracted with a fat solvent.
  • the serum which is thereby essentially free of lipoprotein is reconstituted with water to provide a base liquid blood serum.
  • materials can be added to the base liquid blood serum to provide the final control standard.
  • the method of preparing the liquid blood serum control standard of this invention is particularly adapted for use with defibrinated blood plasma containing high concentrations of the inorganic ions: sodium, potassium and calcium, for example, stored blood plasma containing the anticoagulants sodium citrate, potassium oxalate, heparin sodium or sodium ethylene diamine tetraacetate, citrated blood plasma (containing sodium citrate or sodium citrate and dextrose), ACD blood plasma (containing citric acid, sodium citrate and dextrose), and CPD blood plasma (containing citrate, phosphate and dextrose).
  • stored blood plasma containing the anticoagulants sodium citrate, potassium oxalate, heparin sodium or sodium ethylene diamine tetraacetate
  • citrated blood plasma containing sodium citrate or sodium citrate and dextrose
  • ACD blood plasma containing citric acid, sodium citrate and dextrose
  • CPD blood plasma containing citrate, phosphate and dextrose
  • Defibrination can be carried out by the addition of, for example, calcium ions to citrated blood or Polybrene (hexadimethrene bromide) to heparinized blood.
  • strong acid cation exchange resins which can be employed in the practice of this invention are the sulfonic acid cation exchange resins.
  • These resins can be, for example, sulfonated phenol, sulfonated polystyrene, sulfonated phenolformaldehyde, sulfonated oopolymers of monoalkenyl aromatic hydrocarbons with from about 0.5 to about 25 weight percent of a dialkenyl cross-linking compound, e.g., divinylbenzene, divenyltoluene, divinylxylene and the like resins.
  • a dialkenyl cross-linking compound e.g., divinylbenzene, divenyltoluene, divinylxylene and the like resins.
  • Resins of this type are commercially available under the trademarks Dowex 50, (Dow Chemical Co.), Amberlite IR-120 (Rohm & Haas Co., Inc.), Driolite C-3 (Chemical Process Co., Inc.), and Diaion SK #1 (Mitsubishi Chemical Industiries Ltd.).
  • Dowex 50 is a sulfonated polystyrene cross-linked with divinylbenzene such as described in US. Pat. 2,366,007.
  • a preferred resin is a polystyrene nuclear sulfonic acid ion exchange resin on the hydrogen cycle such as Dowex 50, 50 to 100 mesh.
  • the blood serum is mixed with the ion exchange resin preferably in proportions of from about 25 to about 100 grams of resin per liter of serum.
  • mixing about 40 grams of Dowex 50 resin with one liter of serum has been found to provide excellent results whereby the sodium ion level is reduced from a range of about 165 to 205 milliequivalents per liter of serum to a range of about to milliequivalents per liter of serum.
  • a preferred alkaline reagent for maintaining or adjusting the pH of the serum to about its original level is a tris buffer [tri(hydroxy methyl)aminomethane].
  • the tris buffer preferably is an aqueous solution of from about 30 to about 50 grams of tris per liter of distilled water and has a pH of from about 5.8 to about 6.8 prior to drying.
  • an important blood component to be contained in the control standard is urea nitrogen or blood urea nitrogen (BUN).
  • BUN urea nitrogen or blood urea nitrogen
  • the BUN preferably is determined by the Bertholet test or by a modified-Bertholet test such as described, for example, in US. Pats. 3,119,751, 3,467,499 and Re. 26,125. It has been found, however, that the use of tris buffer interferes with the determination of BUN by these Bertholet or modified- Bertholet tests. Unexpectedly, the use of lithium hydroxide or strontium hydroxide does not interfere with these BUN tests and, at the same time, retains the unique advantages of the tris buffer in being free from potassium, sodium, calcium and ammonium ions.
  • the preferred lithium hydroxide employed in this invention preferably is an aqueous solution of from about 50 to about 70 grams of lithium hydroxide per liter of distilled Water.
  • the drying of the resin-treated and pH-ad usted serum preferably is carried out by conventional freeze dry ng or lyophilization methods whereby the serium is dried from the frozen state under a high vacuum and ice or other frozen solvent rapidly sublimes to yield a porous solid.
  • fat solvents which can be employed in this invention are organic solvents such as esters, ethers, ketones, hydrocarbons and chlorinated hydrocarbons.
  • organic solvents such as light paraffinic petroleum fractions or naphthas, particularly of the hexane or heptane types, cyclic hydrocarbons such as cyclohexane, chlorinated solvents such as chloroform and carbon tetrachloride, ethers such as diethyl ether, and ketones such as acetone and butanone.
  • a preferred fat sol vent is a fluorocarbon or Freon such as monofiuorotr chloromethane, dichlorodifluoromethane, monochlorodifiuoromethane, monofluorodichloromethane and various mixtures thereof.
  • the solvent extraction is carried out by thoroughly admixing the dried serum with the fat solvent and then separating the undissolved material from the fat solvent.
  • the dried serum is mixed with the solvent preferably in proportions of from about 30 to about 90 grams of serum per liter of solvent for about to about 60 minutes with stirring.
  • the fat solvent can be removed by filtering and the like separation procedures, with any residual solvent being allowed to evaporate from the retained dry serum particles.
  • the serum which is the essentially free from lipoprotein is reconstituted to about its original volume or in other suitable proportions with water, preferably distilled water, to provide the base liquid blood serum control standard.
  • Illustrative of the blood serum components which can be included in the control standard of this invention are substances selected from the group consisting of albumin, acid phosphatase, alkaline phosphatase, amylase, bilirubin, calcium, carbon dioxide, chloride, cholesterol, creatinine, glucose, haemoglobin, lactic dehydrogenase, phosphorous, potassium, sodium, total protein, transaminases such as serum glutamic oxalacetic transaminase and serum glutamic pyruvic transaminase, triglycerides, urea nitrogen, uric acid and other such substances found in blood serum.
  • transaminases such as serum glutamic oxalacetic transaminase and serum glutamic pyruvic transaminase, triglycerides, urea nitrogen, uric acid and other such substances found in blood serum.
  • a preferred control standard of this invention contains predetermined concentrations of the following blood serum components in admixture: sodium, potassium, chloride, phosphorous, calcium, BUN, glucose, uric acid, creatinine, total protein, protein bound iodine (FBI) and carbon dioxide (HCO).
  • the base liquid serum can be brought to the desired predetermined levels of these components by adding suitable amounts of appropriate materials containing the components.
  • the following materials can be added, respectively: sodium acetate, potassium hydroxide, sodium chloride, potassium dihydrogen phosphate, calcium chlo ride, urea, glucose, uric acid, creatinine, dried blood serum, thyroxine and sodium bicarbonate.
  • This control standard is storage stable at customary refrigerated temperatures (4 C.) for three months and provides suitable assay values for these components.
  • Citrated human blood serum is defibrinated by the addition of calcium ions followed by filtration.
  • the resulting serum is then mixed with a polystyrene nuclear sulfonic acid ion exchange resin on the hydrogen cycle (Dowex 50, 50 to 100 mesh) in a ratio of 40 grams of resin per liter of serum to reduce the level of the sodium and potassium ion (and calcium ion when present) in the serum.
  • a polystyrene nuclear sulfonic acid ion exchange resin on the hydrogen cycle (Dowex 50, 50 to 100 mesh) in a ratio of 40 grams of resin per liter of serum to reduce the level of the sodium and potassium ion (and calcium ion when present) in the serum.
  • the pH of the serum is maintained at or adjusted to a level of about 62:02 with an aqueous solution of lithium hydroxide.
  • the sodium ion level is reduced by this ion exchange treatment from a range of about 165 to 205 milliequivalents per liter of serum to a range of about to milliequivalents per liter of serum.
  • the pH of the final treated serum is checked and adjusted to 62:02 with lithium hydroxide.
  • the resin-treated and pH-adjusted serum is lyophilized and then extracted with Freon TF (trichlorotrifiuoroethane) by thoroughly admixing 75 grams of the dried serum with 1500 ml. of the Freon.
  • the mixture is filtered through Whatman #1 filter paper and the residual solid material is spread to dry.
  • the dry material is then reconstituted with distilled Water and filtered to remove any remaining particulate matter. This product is retained as the base liquid blood serum control standard and assayed for desired components.
  • control standards were prepared having predetermined low, medium and high concentrations as follows:
  • the above prepared, essentially lipoprotein-free dried serum is divided into three parts and reconstituted to three different levels with distilled Water using the below-stated protein levels as the base.
  • the reconstituted samples were assayed as follows:
  • the adjusted control standard material is sterile filtered through a Millipore filter (0.22 micron) and placed in vials for use as therfinal control standards which can then be made available to clinical laboratories and other such analytical and testing laboratories having a need for blood serum control standards.
  • a liquid blood serum control standard from anticoagulant-stored blood plasma comprising thoroughly admixing the defibriuated plasma with a strong cation exchange resin to substantially reduce the sodium, potassium and calcium ion level in the serum followed by drying, removing the lipoprotein component by extraction with a fat-solvent and then reconstituting the serum with water the pH of said resintreated serum being adjusted to or maintained at a pH of from about 5.8 to about 6.8 with a reagent selected from the group consisting of aqueous lithium hydroxide, strontium hydroxide and tris(hydroxymethyD-amiuomethane.
  • ion exchange resin is a polystyrene nuclear sulfonic acid ion exchange resin on the hydrogen cycle.
  • the cation exchange resin is a polystyrene nuclear sulfonic acid ion exchange resin on the hydrogen cycle and is mixed with the defibrinated plasma in proportions of from about 25 to about 100 grams of resin per liter of said plasma, in which the fat-solvent is a chlorinated hydrocarbon and is mixed with the dried serum in proportions of from about .30 to about grams of resin per liter of solvent.
  • a liquid blood serum control standard comprising anticoagulant-stored blood plasma which is defibrinated, resin-treated with strong cation exchange resin to substantially reduce the sodium, potassium and calcium ion level followed by drying, removing the lipoprotein component by extraction with a fat-solvent and then reconstituting the serum with water, the pH of said resintreated serum being adjusted to or maintained at a pH of from about 5.8 to about 6.8 with a reagent selected from the group consisting of aqueous lithium hydroxide, strontium hydroxide and tris(hydroxymethyl)-aminomethane.

Abstract

A LIQUID CONTROL STANDARD FOR USE IN THE ANALYSIS OF BLOOD SERUM, WHICH STANDARD IS PREPARED FROM ANTICOAGULANTSTORED BLOOD PLASMA BY TREATING THE DEBFIBRINATED PLASMA WITH ION EXCHANGE RESIN TO REDUCE THE ALKALI AND ALKALINEEARTH METAL CATION LEVEL FOLLOWED BY DRYING, REMOVING THE LIPOPROTEIN COMPONENT BY EXTRACTION WITH A FAT SOLVENT AND THEN RECONSTITUTING THE PRODUCT WITH WATER.

Description

3,682,835 Patented Aug. 8, 1972 3,682,835 LIQUID BLOOD SERUM CONTROL STANDARD Allan L. Louderback, Temple City, Calif., assignor to Baxter Laboratories, Inc., Morton Grove, Ill. No Drawing. Filed Nov. 24, 1970, Ser. No. 92,533 Int. Cl. (109k 3/00 US. Cl. 252-408 5 Claims ABSTRACT OF THE DISCLOSURE A liquid control standard for use in the analysis of blood serum, which standard is prepared from anticoagulantstored blood plasma by treating the defibrinated plasma with ion exchange resin to reduce the alkali and alkalineearth metal cation level followed by drying, removing the lipoprotein component by extraction with a fat solvent and then reconstituting the product with water.
This invention relates to a liquid blood serum control standard and method of preparation thereof.
Blood serum is a complex biological fluid containing numerous components of substantial physiological importance. In the normal or average healthy person the concentrations of these components fall within certain reasonably well-defined limits. When one or more of these components is determined upon analysis to fall outside of these acceptable limits, various diseases or pathological conditions of the body systems are indicated.
In recent years various automated procedures have been developed for conveniently analyzing multiple components of blood serum. Illustrative of the analytical equipment for these purposes are the Technicon AutoAnalyzer, the
Warner Chillcott Robot Chemist and the Beckman Dis- 3 crete Analyzer. These instruments are capable of rapidly and sequentially determining the concentrations of a host of blood serum components in a single sample, for example, up to a dozen or more values.
In the performance of the analytical tests made by the above and similar equipment on blood serum and other biological samples, it is necessary to use laboratory standard materials or so-called reference or control standards for purposes of calibration and control of the instrument. Accurate results in the use of these instruments, particularly in the case of multi-automated procedures, are dependent upon rigid and constant standardization of the biochemical determinations.
Illustrative of the control standards used in actual practice is the freeze-dried serum which is reconstituted with aqueous ammonium bicarbonate prior to use as described in US. Pat. 3,466,249. For certain purposes, a complete liquid control standard which does not require such reconstitution would be convenient and find much use in practice.
Accordingly, it is an object of this invention to provide a liquid blood serum control standard.
It is another object of this invention to provide a stable blood serum reference standard which can be used for the direct calibration and control of multi-automated analytical procedures.
Other objects and advantages of the invention Will be apparent to those skilled in the art after reading the present disclosure.
In accordance with the present invention, liquid blood serum is treated with a strong acid cation exchange resin to reduce the sodium, potassium and calcium level in the serum, and the pH of the serum is maintained at, or adjusted to, about its original level by sufficient alkaline reagent which does not contain any sodium, potassium, calcium or ammonium ions. The resin-treated and pH-adjusted serum is then dried and the lipoprotein component is extracted with a fat solvent. The serum which is thereby essentially free of lipoprotein is reconstituted with water to provide a base liquid blood serum. Depending upon the analysis of the starting material and the desired concentration of various components in the final product, materials can be added to the base liquid blood serum to provide the final control standard.
The method of preparing the liquid blood serum control standard of this invention is particularly adapted for use with defibrinated blood plasma containing high concentrations of the inorganic ions: sodium, potassium and calcium, for example, stored blood plasma containing the anticoagulants sodium citrate, potassium oxalate, heparin sodium or sodium ethylene diamine tetraacetate, citrated blood plasma (containing sodium citrate or sodium citrate and dextrose), ACD blood plasma (containing citric acid, sodium citrate and dextrose), and CPD blood plasma (containing citrate, phosphate and dextrose).
Defibrination can be carried out by the addition of, for example, calcium ions to citrated blood or Polybrene (hexadimethrene bromide) to heparinized blood.
Examples of strong acid cation exchange resins which can be employed in the practice of this invention are the sulfonic acid cation exchange resins. These resins can be, for example, sulfonated phenol, sulfonated polystyrene, sulfonated phenolformaldehyde, sulfonated oopolymers of monoalkenyl aromatic hydrocarbons with from about 0.5 to about 25 weight percent of a dialkenyl cross-linking compound, e.g., divinylbenzene, divenyltoluene, divinylxylene and the like resins. Resins of this type are commercially available under the trademarks Dowex 50, (Dow Chemical Co.), Amberlite IR-120 (Rohm & Haas Co., Inc.), Driolite C-3 (Chemical Process Co., Inc.), and Diaion SK #1 (Mitsubishi Chemical Industiries Ltd.). A preferred resin is Dowex 50 which is a sulfonated polystyrene cross-linked with divinylbenzene such as described in US. Pat. 2,366,007.
Other suitable strong acid cation exchange resins which can be used in this invention will be apparent to those skilled in the art and can be prepared by reference to a text such as Kunin, Ion Exchange Resins, John Wiley & Sons, Inc., New York, 1950.
A preferred resin is a polystyrene nuclear sulfonic acid ion exchange resin on the hydrogen cycle such as Dowex 50, 50 to 100 mesh.
The blood serum is mixed with the ion exchange resin preferably in proportions of from about 25 to about 100 grams of resin per liter of serum. Thus, mixing about 40 grams of Dowex 50 resin with one liter of serum has been found to provide excellent results whereby the sodium ion level is reduced from a range of about 165 to 205 milliequivalents per liter of serum to a range of about to milliequivalents per liter of serum.
A preferred alkaline reagent for maintaining or adjusting the pH of the serum to about its original level is a tris buffer [tri(hydroxy methyl)aminomethane]. The tris buffer preferably is an aqueous solution of from about 30 to about 50 grams of tris per liter of distilled water and has a pH of from about 5.8 to about 6.8 prior to drying.
According to one aspect of this invention, an important blood component to be contained in the control standard is urea nitrogen or blood urea nitrogen (BUN). The BUN preferably is determined by the Bertholet test or by a modified-Bertholet test such as described, for example, in US. Pats. 3,119,751, 3,467,499 and Re. 26,125. It has been found, however, that the use of tris buffer interferes with the determination of BUN by these Bertholet or modified- Bertholet tests. Unexpectedly, the use of lithium hydroxide or strontium hydroxide does not interfere with these BUN tests and, at the same time, retains the unique advantages of the tris buffer in being free from potassium, sodium, calcium and ammonium ions. The preferred lithium hydroxide employed in this invention preferably is an aqueous solution of from about 50 to about 70 grams of lithium hydroxide per liter of distilled Water.
The drying of the resin-treated and pH-ad usted serum preferably is carried out by conventional freeze dry ng or lyophilization methods whereby the serium is dried from the frozen state under a high vacuum and ice or other frozen solvent rapidly sublimes to yield a porous solid.
The lipoprotein content of the dried serum is then removed by extraction with a fat solvent, Examples of fat solvents which can be employed in this invention are organic solvents such as esters, ethers, ketones, hydrocarbons and chlorinated hydrocarbons. Examples of these organic solvents are hydrocarbons such as light paraffinic petroleum fractions or naphthas, particularly of the hexane or heptane types, cyclic hydrocarbons such as cyclohexane, chlorinated solvents such as chloroform and carbon tetrachloride, ethers such as diethyl ether, and ketones such as acetone and butanone. A preferred fat sol vent is a fluorocarbon or Freon such as monofiuorotr chloromethane, dichlorodifluoromethane, monochlorodifiuoromethane, monofluorodichloromethane and various mixtures thereof.
The solvent extraction is carried out by thoroughly admixing the dried serum with the fat solvent and then separating the undissolved material from the fat solvent. The dried serum is mixed with the solvent preferably in proportions of from about 30 to about 90 grams of serum per liter of solvent for about to about 60 minutes with stirring. The fat solvent can be removed by filtering and the like separation procedures, with any residual solvent being allowed to evaporate from the retained dry serum particles.
The serum which is the essentially free from lipoprotein is reconstituted to about its original volume or in other suitable proportions with water, preferably distilled water, to provide the base liquid blood serum control standard.
Illustrative of the blood serum components which can be included in the control standard of this invention are substances selected from the group consisting of albumin, acid phosphatase, alkaline phosphatase, amylase, bilirubin, calcium, carbon dioxide, chloride, cholesterol, creatinine, glucose, haemoglobin, lactic dehydrogenase, phosphorous, potassium, sodium, total protein, transaminases such as serum glutamic oxalacetic transaminase and serum glutamic pyruvic transaminase, triglycerides, urea nitrogen, uric acid and other such substances found in blood serum.
A preferred control standard of this invention contains predetermined concentrations of the following blood serum components in admixture: sodium, potassium, chloride, phosphorous, calcium, BUN, glucose, uric acid, creatinine, total protein, protein bound iodine (FBI) and carbon dioxide (HCO The base liquid serum can be brought to the desired predetermined levels of these components by adding suitable amounts of appropriate materials containing the components. For the twelve foregoing blood serum components, the following materials can be added, respectively: sodium acetate, potassium hydroxide, sodium chloride, potassium dihydrogen phosphate, calcium chlo ride, urea, glucose, uric acid, creatinine, dried blood serum, thyroxine and sodium bicarbonate. This control standard is storage stable at customary refrigerated temperatures (4 C.) for three months and provides suitable assay values for these components.
The following examples will further illustrate the present invention although the invention is not limited to these specific examples.
EXAMPLE 1 Citrated human blood serum is defibrinated by the addition of calcium ions followed by filtration. The resulting serum is then mixed with a polystyrene nuclear sulfonic acid ion exchange resin on the hydrogen cycle (Dowex 50, 50 to 100 mesh) in a ratio of 40 grams of resin per liter of serum to reduce the level of the sodium and potassium ion (and calcium ion when present) in the serum. As the hydrogen ion is released into the serum by the exchange for sodium and potassium ions, the pH of the serum is maintained at or adjusted to a level of about 62:02 with an aqueous solution of lithium hydroxide. The sodium ion level is reduced by this ion exchange treatment from a range of about 165 to 205 milliequivalents per liter of serum to a range of about to milliequivalents per liter of serum. The pH of the final treated serum is checked and adjusted to 62:02 with lithium hydroxide. The resin-treated and pH-adjusted serum is lyophilized and then extracted with Freon TF (trichlorotrifiuoroethane) by thoroughly admixing 75 grams of the dried serum with 1500 ml. of the Freon. The mixture is filtered through Whatman #1 filter paper and the residual solid material is spread to dry. The dry material is then reconstituted with distilled Water and filtered to remove any remaining particulate matter. This product is retained as the base liquid blood serum control standard and assayed for desired components.
In this example, three control standards were prepared having predetermined low, medium and high concentrations as follows:
Control standard concentration I N o 1 N 0 3 No 1, low medium high concenconcenconcen- Component tration traticn tration Sodium (meet/l) Potassium (meq./l.) 3 5 Calcium (Ing., percent) 6 10 14 Chloride (meq./l.) 80 100 120 BUN (mg., percent)... 10 40 so Creatinine (mg, percent) 1.0 4.0 7.0 Urlc acid (mg, percent) 3. 5 7. 5 11. 5 Glucose (mg, ercent) 80 400 Total protein (2111., 4. 5 6.0 7. 2 Albumin (mg percent). 2. 7 3.6 4.3 COz(I-ICOa)- 18 25 35 PB! g, percent) 4. 3 6.0 9.0 P (mg. percent). 3 8 13 1 Each concentration is within i10% ol the stated value.
In order to prepare these three levels, the above prepared, essentially lipoprotein-free dried serum is divided into three parts and reconstituted to three different levels with distilled Water using the below-stated protein levels as the base. The reconstituted samples were assayed as follows:
Reconstituted sample concentration Component N0. 1 N 0. 2 No.3
Sodium (meqJl. 72. 8 96. 9 102 Potassium (meq ll.) 1. 14 1. 52 1.6 Calcium (mg percent). 3. 93 5. 23 5. 5 Chloride (meq./l.) 72.11 95.95 101 BUN (mg, pereent). 7. 14 9. 5 10 Creatlnino (mg, percent) 0. 57 0.76 0.8 Urle acid (mg, percent) 2.14 2. 7 3 Glucose (mg, percent) 61.4 81.7 86 Total protein (mg 4. 5 6.0 6.3 Albumin (mg percent)- 2. 7 3. 6 3. 8 COAHCOr) 1. 76 2.35 2. 47 PBI g, percent). 3.07 4.09 4. 3 P (mg, percent) 2.43 3.23 3.4
Reconstituted Samples 1, 2 and 3 were then used to make the foregoing control standards of low, medium and high concentrations by addition of suitable amounts of the appropriate materials as follows:
Amount added to samples Material added No. 1 N o. 2 N0. 3
Sodium acetate (grams) 2. 38 1. 53 0. 467 Potassium hydroxide (m1 1.01 1. 16 1.382 Calcium chloride (grams) 3. 45 7. 97 0. 142 Sodium chloride (grams)... 0. 239 0.058 0. 513 Urea (grams) 0. 034 0. 366 0. 84 Creatim'ne (mg.) 2. 5s 19. 44 37. 2 Uric acid (grams) 0. 008 0. 029 0. 051 Glucose (grams) 0.112 0.470 1. 884 Dried serum (grams).-- 0 9 Sodium bicarbonate (mg 818. 1,141. 6 1, 639. 5 Thyroxine 1.) 20. 2 31. 3 77. Potassium dihydrogen phosphate (grams) 1. 500 0. 126 0. 253
The adjusted control standard material is sterile filtered through a Millipore filter (0.22 micron) and placed in vials for use as therfinal control standards which can then be made available to clinical laboratories and other such analytical and testing laboratories having a need for blood serum control standards.
Various other examples and modifications of the foregoing examples will be apparent to those skilled in the art after reading the foregoing specification and the appended claims without departing from the spirit and scope of the invention. All such further examples and modifications are included within the scope of the invention as defined in the following claims.
What is claimed is:
1. The method of making a liquid blood serum control standard from anticoagulant-stored blood plasma comprising thoroughly admixing the defibriuated plasma with a strong cation exchange resin to substantially reduce the sodium, potassium and calcium ion level in the serum followed by drying, removing the lipoprotein component by extraction with a fat-solvent and then reconstituting the serum with water the pH of said resintreated serum being adjusted to or maintained at a pH of from about 5.8 to about 6.8 with a reagent selected from the group consisting of aqueous lithium hydroxide, strontium hydroxide and tris(hydroxymethyD-amiuomethane.
2. The method of claim 1 in which the reagent for pH adjustment or maintenance is aqueous lithium hydroxide.
3. The method of claim 1 in which the ion exchange resin is a polystyrene nuclear sulfonic acid ion exchange resin on the hydrogen cycle.
4. The method of claim 1 in which the cation exchange resin is a polystyrene nuclear sulfonic acid ion exchange resin on the hydrogen cycle and is mixed with the defibrinated plasma in proportions of from about 25 to about 100 grams of resin per liter of said plasma, in which the fat-solvent is a chlorinated hydrocarbon and is mixed with the dried serum in proportions of from about .30 to about grams of resin per liter of solvent.
5. A liquid blood serum control standard comprising anticoagulant-stored blood plasma which is defibrinated, resin-treated with strong cation exchange resin to substantially reduce the sodium, potassium and calcium ion level followed by drying, removing the lipoprotein component by extraction with a fat-solvent and then reconstituting the serum with water, the pH of said resintreated serum being adjusted to or maintained at a pH of from about 5.8 to about 6.8 with a reagent selected from the group consisting of aqueous lithium hydroxide, strontium hydroxide and tris(hydroxymethyl)-aminomethane.
References Cited UNITED STATES PATENTS 3,466,249 9/1969 Anderson 252--408 ROBERT F. BURNETT, Primary Examiner M. E. McC-AMISH, Assistant Examiner US. Cl. X.R.
US92533A 1970-11-24 1970-11-24 Liquid blood serum control standard Expired - Lifetime US3682835A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9253370A 1970-11-24 1970-11-24

Publications (1)

Publication Number Publication Date
US3682835A true US3682835A (en) 1972-08-08

Family

ID=22233688

Family Applications (1)

Application Number Title Priority Date Filing Date
US92533A Expired - Lifetime US3682835A (en) 1970-11-24 1970-11-24 Liquid blood serum control standard

Country Status (15)

Country Link
US (1) US3682835A (en)
AU (1) AU464164B2 (en)
BE (1) BE775340A (en)
CA (1) CA962193A (en)
CH (1) CH542446A (en)
DE (1) DE2156604A1 (en)
ES (1) ES397245A1 (en)
FR (1) FR2116164A5 (en)
GB (1) GB1359232A (en)
IL (1) IL38093A (en)
IT (1) IT941771B (en)
LU (1) LU64243A1 (en)
NL (1) NL7116167A (en)
SE (1) SE376309B (en)
ZA (1) ZA717532B (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897363A (en) * 1973-08-10 1975-07-29 Baxter Laboratories Inc Blood control standard
US3955925A (en) * 1973-11-12 1976-05-11 Proksch Gary J Preparation of optically clear serum
US3958939A (en) * 1975-01-08 1976-05-25 Coulter Electronics, Inc. Method for clarification of lipemic serum
US4007008A (en) * 1975-07-30 1977-02-08 Becker Milton J Preparation of reference serum from animal blood
US4011045A (en) * 1975-02-14 1977-03-08 Bonderman Dean P Turbidity reduction in triglyceride standards
US4045176A (en) * 1975-06-13 1977-08-30 Proksch Gary J Preparation of optically clear serum
US4054488A (en) * 1975-08-14 1977-10-18 Marbach Edward P Preservation of glucose in blood samples
US4056484A (en) * 1974-12-31 1977-11-01 Behringwerke Aktiengesellschaft Stable blood plasma, process for preparing it and its use as comparative plasma in coagulation tests
US4116635A (en) * 1977-03-14 1978-09-26 Jaeger Mark A General purpose in vitro anticoagulant
US4127502A (en) * 1977-06-10 1978-11-28 Eastman Kodak Company Stabilizers for reconstituted, lyophilized samples
DE2927841A1 (en) * 1978-07-17 1980-02-07 Beckman Instruments Inc METHOD FOR PRODUCING A BIOLOGICAL COMPOSITION FOR USE AS A BLOOD SERUM REFERENCE COMPOSITION FOR DIAGNOSTIC ANALYZING PURPOSES
US4190573A (en) * 1974-02-14 1980-02-26 Behringwerke Aktiengesellschaft Process for the isolation of the polyvalent proteinase inhibitor
US4219440A (en) * 1979-06-06 1980-08-26 Coulter Electronics, Inc. Multiple analysis hematology reference control reagent and method of making the same
US4264471A (en) * 1979-06-04 1981-04-28 E. I. Du Pont De Nemours And Company Serum and plasma clarification process
US4324687A (en) * 1979-02-15 1982-04-13 Louderback Allan Lee Blood biochemistry control standard
US4325832A (en) * 1979-03-05 1982-04-20 Beckman Instruments, Inc. Enzyme reference composition
US4789545A (en) * 1986-03-31 1988-12-06 New York Blood Center, Inc. Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof
US4806486A (en) * 1985-01-31 1989-02-21 Stichting Gastransport Calibration liquid for ion-specific electrodes, process for preparing them and their application
US4956299A (en) * 1986-12-31 1990-09-11 Ciba Corning Diagnostics Corp. Complement stabilization
US5028542A (en) * 1990-02-07 1991-07-02 Boehringer Mannheim Corporation Glucose measurement control reagent and method of making the same
US6268481B1 (en) 1997-05-29 2001-07-31 Medical Analysis Systems, Inc. Covalently coupled troponin complexes
US6509192B1 (en) * 1992-02-24 2003-01-21 Coulter International Corp. Quality control method
US20040137419A1 (en) * 2003-01-15 2004-07-15 V.I. Technologies, Inc. Methods for removing microbicidal compounds from compositions
CN101930009A (en) * 2009-11-19 2010-12-29 首都医科大学附属北京朝阳医院 Serum calcium standard substance

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897363A (en) * 1973-08-10 1975-07-29 Baxter Laboratories Inc Blood control standard
US3955925A (en) * 1973-11-12 1976-05-11 Proksch Gary J Preparation of optically clear serum
US4190573A (en) * 1974-02-14 1980-02-26 Behringwerke Aktiengesellschaft Process for the isolation of the polyvalent proteinase inhibitor
US4056484A (en) * 1974-12-31 1977-11-01 Behringwerke Aktiengesellschaft Stable blood plasma, process for preparing it and its use as comparative plasma in coagulation tests
US3958939A (en) * 1975-01-08 1976-05-25 Coulter Electronics, Inc. Method for clarification of lipemic serum
US4011045A (en) * 1975-02-14 1977-03-08 Bonderman Dean P Turbidity reduction in triglyceride standards
US4045176A (en) * 1975-06-13 1977-08-30 Proksch Gary J Preparation of optically clear serum
US4007008A (en) * 1975-07-30 1977-02-08 Becker Milton J Preparation of reference serum from animal blood
US4054488A (en) * 1975-08-14 1977-10-18 Marbach Edward P Preservation of glucose in blood samples
US4116635A (en) * 1977-03-14 1978-09-26 Jaeger Mark A General purpose in vitro anticoagulant
US4127502A (en) * 1977-06-10 1978-11-28 Eastman Kodak Company Stabilizers for reconstituted, lyophilized samples
DE2825391A1 (en) * 1977-06-10 1978-12-21 Eastman Kodak Co SERUM MATRIX OR SERUM DERIVED COMPOSITION
DE2927841A1 (en) * 1978-07-17 1980-02-07 Beckman Instruments Inc METHOD FOR PRODUCING A BIOLOGICAL COMPOSITION FOR USE AS A BLOOD SERUM REFERENCE COMPOSITION FOR DIAGNOSTIC ANALYZING PURPOSES
US4324687A (en) * 1979-02-15 1982-04-13 Louderback Allan Lee Blood biochemistry control standard
US4325832A (en) * 1979-03-05 1982-04-20 Beckman Instruments, Inc. Enzyme reference composition
US4264471A (en) * 1979-06-04 1981-04-28 E. I. Du Pont De Nemours And Company Serum and plasma clarification process
US4219440A (en) * 1979-06-06 1980-08-26 Coulter Electronics, Inc. Multiple analysis hematology reference control reagent and method of making the same
US4806486A (en) * 1985-01-31 1989-02-21 Stichting Gastransport Calibration liquid for ion-specific electrodes, process for preparing them and their application
US4789545A (en) * 1986-03-31 1988-12-06 New York Blood Center, Inc. Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof
US4956299A (en) * 1986-12-31 1990-09-11 Ciba Corning Diagnostics Corp. Complement stabilization
US5028542A (en) * 1990-02-07 1991-07-02 Boehringer Mannheim Corporation Glucose measurement control reagent and method of making the same
US6509192B1 (en) * 1992-02-24 2003-01-21 Coulter International Corp. Quality control method
US20030092184A1 (en) * 1992-02-24 2003-05-15 Coulter International Corporation Quality control method
US20050095719A1 (en) * 1992-02-24 2005-05-05 Young Carole J. Quality control method
US6268481B1 (en) 1997-05-29 2001-07-31 Medical Analysis Systems, Inc. Covalently coupled troponin complexes
US20040137419A1 (en) * 2003-01-15 2004-07-15 V.I. Technologies, Inc. Methods for removing microbicidal compounds from compositions
WO2004065008A1 (en) * 2003-01-15 2004-08-05 V.I. Technologies, Inc. Methods for removing microbicidal compounds from compositions
CN101930009A (en) * 2009-11-19 2010-12-29 首都医科大学附属北京朝阳医院 Serum calcium standard substance
CN101930009B (en) * 2009-11-19 2013-09-11 首都医科大学附属北京朝阳医院 Serum calcium standard substance

Also Published As

Publication number Publication date
FR2116164A5 (en) 1972-07-07
CH542446A (en) 1973-09-30
LU64243A1 (en) 1972-06-02
SE376309B (en) 1975-05-12
IL38093A0 (en) 1972-01-27
BE775340A (en) 1972-03-16
ES397245A1 (en) 1975-03-01
DE2156604A1 (en) 1972-05-31
IL38093A (en) 1974-07-31
AU464164B2 (en) 1975-08-21
ZA717532B (en) 1972-07-26
NL7116167A (en) 1972-05-26
CA962193A (en) 1975-02-04
IT941771B (en) 1973-03-10
GB1359232A (en) 1974-07-10
AU3554071A (en) 1973-05-17

Similar Documents

Publication Publication Date Title
US3682835A (en) Liquid blood serum control standard
US3466249A (en) Blood serum reference standard for multi-automated analytical procedures
Levin et al. Clottable protein in Limulus: its localization and kinetics of its coagulation by endotoxin
Seegers et al. Further studies on the purification of thrombin
Lum et al. A comparison of serum versus heparinized plasma for routine chemistry tests
US4731330A (en) Whole blood control sample
US4045176A (en) Preparation of optically clear serum
US3640896A (en) Process for stabilizing fowl red blood cells
US4290774A (en) Purification of lipoprotein cholesterol for use as a cholesterol reference material
US4389490A (en) Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; and diluents thereof
US3235337A (en) Diagnostic compositions and test indicators
US3574137A (en) Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium
US3629142A (en) Reference standard blood serum for the calibration of automatic blood serum analyzing apparatus
US3728226A (en) Blood serum analytical control standard
Neuman et al. The surface chemistry of bone. VII. The hydration shell1
EP0019939B1 (en) Serum and plasma clarification process
Farese et al. A membrane ultrafiltration procedure for determining diffusible calcium in serum
Dagneaux et al. Oxalic acid determination in plasma
Jones The estimation of free sugars in skeletal muscle of codling (Gadus callarias) and herring (Clupea harengus)
US3993585A (en) Elevated human lipids control
CN110997933B (en) Methods and compositions for stabilizing cell-free nucleic acids and cells
CA2292595A1 (en) Anti-coagulation of blood, blood plasma or synovial fluid products
De Castro et al. Lyophilization: a useful approach to the automation of analytical processes?
Iampietro et al. pH-dependent lysis of canine erythrocytes.
US3897363A (en) Blood control standard

Legal Events

Date Code Title Description
AS Assignment

Owner name: COOPER LABORATORES, INC., 3145 PORTER DRIVE, PALO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:BAXTER TRAVENOL LABORATORIES, INC., A CORP. OF DE;REEL/FRAME:004067/0785

Effective date: 19820917

AS Assignment

Owner name: TECHNICON INSTRUMENTS CORPORATION, 511 BENEDICT AV

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:COOPER LABORATORIES, INC.,;REEL/FRAME:004926/0396

Effective date: 19880628